Genetic Variants of CYP2D6 Gene and Cancer Risk: A HuGE Systematic Review and Meta-analysis |
Zhou, Li-Ping
(Department of Laboratory Medicine, the First Affiliated Hospital of China Medical University)
Luan, Hong (Department of Laboratory Medicine, the First Affiliated Hospital of China Medical University) Dong, Xi-Hua (Department of Laboratory Medicine, the First Affiliated Hospital of China Medical University) Jin, Guo-Jiang (Department of Laboratory Medicine, the First Affiliated Hospital of China Medical University) Man, Dong-Liang (Department of Laboratory Medicine, the First Affiliated Hospital of China Medical University) Shang, Hong (Department of Laboratory Medicine, the First Affiliated Hospital of China Medical University) |
1 | Fukatsu T, Hirokawa Y, Araki T, et al (2004). Genetic polymorphisms of hormone-related genes and prostate cancer risk in the Japanese population. Anticancer Res, 24, 2431-7. |
2 | Gajecka M, Rydzanicz M, Jaskula-Sztul R, et al (2005). CYP1A1, CYP2D6, CYP2E1, NAT2, GSTM1 and GSTT1 polymorphisms or their combinations are associated with the increased risk of the laryngeal squamous cell carcinoma. Mutat Res, 574, 112-23. DOI |
3 | Garcia-Barcelo M, Chow LY, Chiu HF, et al (2000). Genetic analysis of the CYP2D6 locus in a Hong Kong Chinese population. Clin Chem, 46, 18-23. |
4 | Gomes L, Lemos MC, Paiva I, et al (2005). CYP2D6 genetic polymorphisms are associated with susceptibility to pituitary tumors. Acta Med Port, 18, 339-43. |
5 | Gonzalez MV, Alvarez V, Pello MF, et al (1998). Genetic polymorphism of N-acetyltransferase-2, glutathione S-transferase-M1, and cytochromes P450IIE1 and P450IID6 in the susceptibility to head and neck cancer. J Clin Pathol, 51, 294-8. DOI ScienceOn |
6 | Guo Z, Zhou Q, Zhu W, et al (2005). A case-control study on the association between genetic polymorphisms of metabolizing enzymes CYP2D6 and susceptibility to lung cancer. Zhongguo Fei Ai Za Zhi, 8, 89-94. |
7 |
Ji L, Pan S, Marti-Jaun J, et al (2002). Single-step assays to analyze CYP2D6 gene polymorphisms in Asians: allele frequencies and a novel |
8 | Gutman G, Morad T, Peleg B, et al (2009). CYP1A1 and CYP2D6 gene polymorphisms in Israeli Jewish women with cervical cancer. Int J Gynecol Cancer, 19, 1300-2. DOI |
9 | Higgins JP and Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat Med, 21, 1539-58. DOI ScienceOn |
10 | Hu YL, Gao Y, Zhang Q (1998). Genetic polymorphisms of CYP1A1, 2D6 and GSTM1 related with susceptibility to lung cancer. Tumor, 18, 269-71. |
11 | Jin Y, Desta Z, Stearns V, et al (2005). CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst, 97, 30-9. DOI |
12 | Khedhaier A, Hassen E, Bouaouina N, et al (2008). Implication of Xenobiotic Metabolizing Enzyme gene (CYP2E1, CYP2C19, CYP2D6, mEH and NAT2) polymorphisms in breast carcinoma. BMC Cancer, 8, 109. DOI |
13 | Kimura S, Umeno M, Skoda RC, et al (1989). The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am J Hum Genet, 45, 889-904. |
14 | Krajinovic M, Labuda D, Richer C, et al (1999). Susceptibility to childhood acute lymphoblastic leukemia: influence of CYP1A1, CYP2D6, GSTM1, and GSTT1 genetic polymorphisms. Blood, 93, 1496-501. |
15 | Lewis DF (2004). Varieties: the human cytochromes P450. Pharmacogenomics, 5, 305-18. DOI |
16 | Kroemer HK, Eichelbaum M (1995). "It's the genes, stupid". Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sciences, 56, 2285-98. DOI |
17 | Ladona MG, Abildua RE, Ladero JM, et al (1996). CYP2D6 genotypes in Spanish women with breast cancer. Cancer Lett, 99, 23-8. DOI |
18 | Legrand M, Stucker I, Marez D, et al (1996). Influence of a mutation reducing the catalytic activity of the cytochrome P450 CYP2D6 on lung cancer susceptibility. Carcinogenesis, 17, 2267-9. DOI |
19 | Lemos MC, Carrilho F, Rodrigues F, et al (2007). Genetic polymorphism of CYP2D6 influences susceptibility to papillary thyroid cancer. Clin Endocrinol (Oxf), 67, 180-3. DOI |
20 | Lemos MC, Cabrita FJ, Silva HA, et al (1999). Genetic polymorphism of CYP2D6, GSTM1 and NAT2 and susceptibility to haematological neoplasias. Carcinogenesis, 20, 1225-9. DOI |
21 |
Li H, Feng L, Xu Y, et al (2006). The association of CYP2D6 |
22 | Liu CZ, Jiang F, Bian JC, et al (2002). Cytochrome P450 2D6 gene polymorphism and susceptibility to hepatocellular carcinoma research. Chinese Journal of Cancer, 21, 1016-17. |
23 | Li WY, Lai BT, Zhan XP (2004). The relationship between genetic polymorphism of mebabolizing enzymes and the genetic susceptibility to lung cancer. Chin J Epidemiol, 25, 1042-45. |
24 | Liang GY (2005). Studies on susceptibility genes of lung cancer in Chinese Han population and rapid detection techniques of single nucleotides polymorphisms. Southeast University, 1-108. |
25 | Lim JS, Chen XA, Singh O, et al (2011). Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients. Br J Clin Pharmacol, 71, 737-50. DOI |
26 | Majumdar S, Mondal BC, Ghosh M, et al (2008). Association of cytochrome P450, glutathione S-transferase and N-acetyl transferase 2 gene polymorphisms with incidence of acute myeloid leukemia. Eur J Cancer Prev, 17, 125-32. DOI ScienceOn |
27 | Peters JL, Sutton AJ, Jones DR, et al (2006). Comparison of two methods to detect publication bias in meta-analysis. JAMA, 295, 676-80. DOI ScienceOn |
28 | London SJ, Daly AK, Leathart JB, et al (1997). Genetic polymorphism of CYP2D6 and lung cancer risk in African-Americans and Caucasians in Los Angeles County. Carcinogenesis, 18, 1203-14. DOI |
29 | Luo YP, Chen HC, Khan MA, et al (2011). Genetic polymorphisms of metabolic enzymes-CYP1A1, CYP2D6, GSTM1, and GSTT1, and gastric carcinoma susceptibility. Tumour Biol, 32, 215-22. DOI |
30 | Meyer UA, Zanger UM (1997). Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol, 37, 269-96. DOI ScienceOn |
31 | Mochizuki J, Murakami S, Sanjo A, et al (2005). Genetic polymorphisms of cytochrome P450 in patients with hepatitis C virus-associated hepatocellular carcinoma. J Gastroenterol Hepatol, 20, 1191-7. DOI |
32 | Morrow PK, Serna R, Broglio K, et al (2012). Effect of CYP2D6 polymorphisms on breast cancer recurrence. Cancer, 118, 1221-7. DOI |
33 | Singh D, Kashyap A, Pandey RV, Saini KS (2011). Novel advances in cytochrome P450 research. Drug Discov Today, 16, 793-9. DOI |
34 |
Ouerhani S, Marrakchi R, Bouhaha R, et al (2008). The role of |
35 | Roberts RL, Kennedy MA (2006). Rapiddetection of common cytochrome P450 2D6 alleles in Caucasians. Clin Chmi Acta, 366, 348-51. DOI |
36 | Shaw GL, Falk RT, Frame JN, et al (1998). Genetic polymorphism of CYP2D6 and lung cancer risk. Cancer Epidemiol Biomarkers Prev, 7, 215-9. |
37 | Singh MS, Francis PA, Michael M. (2011). Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes. Breast, 20, 111-8. DOI |
38 | Sistonen J, Sajantila A, Lao O, et al (2007). CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics, 17, 93-101. |
39 | Agundez JA (2004). Cytochrome P450 gene polymorphism and cancer. Curr Drug Metab, 5, 211-24. DOI |
40 | Abraham JE, Maranian MJ, Driver KE, et al (2011). CYP2D6 gene variants and their association with breast cancer susceptibility. Cancer Epidemiol Biomarkers Prev, 20, 1255-8. DOI |
41 |
Surekha D, Sailaja K, Rao DN, et al (2010). |
42 | Sobti RC, Al-Badran AI, Sharma S, et al (2005). Genetic polymorphisms of CYP2D6, GSTM1, and GSTT1 genes and bladder cancer risk in North India. Cancer Genet Cytogenet, 156, 68-73. DOI |
43 | Sobti RC, Sharma S, Joshi A, et al (2003). CYP1A1 and CYP2D6 polymorphism and risk of lung cancer in a North Indian population. Biomarkers, 8, 415-28. DOI ScienceOn |
44 | Surekha D, Sailaja K, Rao DN, et al (2010). Association of a CYP17 gene polymorphism with development of breast cancer in India. Asian Pac J Cancer Prev, 11, 1653-7. |
45 | Topic E, Stefanovic M, Ivanisevic AM, et al (2000). The cytochrome P450 2D6 (CYP2D6) gene polymorphism among breast and head and neck cancer patients. Clin Chim Acta, 296, 101-9. DOI |
46 | Torresan C, Oliveira MM, Torrezan GT, et al (2008). Genetic polymorphisms in oestrogen metabolic pathway and breast cancer: a positive association with combined CYP/GST genotypes. Clin Exp Med, 8, 65-71. DOI |
47 | Wexler D, Courtney R, Richards W, et al (2004). Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci, 21, 645-53. DOI |
48 | Agundez JA, Jimenez-Jimenez FJ, Luengo A, et al (1995). Association between the oxidation polymorphism and early onset of Paekinson's disease. Clin Pharmacol Ther, 57, 291-8. DOI |
49 | Agundez JA, Ledesma MC, Benitez J, et al (1995). CYP2D6 genes and risk of liver cancer. Lancet, 345, 830-1. DOI ScienceOn |
50 | von Elm E, Altman DG, Egger M, et al (2007). STROBE Initiative: The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Epidemiology, 18, 800-804. DOI |
51 | Wilkinson GR (2005). Drug metabolism and variability among patients in drug response. N Engl J Med, 352, 2211-21. DOI |
52 | Wundrack I, Meese E, Mullenbach R, Blin N (1994). Debrisoquine hydroxylase gene polymorphism in meningioma. Acta Neuropathol, 88, 472-74. DOI |
53 |
Yan Z, Wu YM, Wu YJ (2008). |
54 |
Zhang L, Liu JL, Zhang YJ, Wang H (2011). Association between |
55 | Altayli E, Gunes S, Yilmaz AF, et al (2009). CYP1A2, CYP2D6, GSTM1, GSTP1, and GSTT1 gene polymorphisms in patients with bladder cancer in a Turkish population. Int Urol Nephrol, 41, 259-66. DOI |
56 | Agundez JA, Martinez C, Ladero JM, et al (1994). Debrisoquin oxidation genotype and susceptibility to lung cancer. Clin Pharmacol Ther, 55, 10-4. DOI |
57 | Agundez JA, Martinez C, Olivera M, et al (1998). Expression in human prostate of drug- and carcinogen-metabolizing enzymes: association with prostate cancer risk. Br J Cancer, 78, 1361-7. DOI |
58 | Agundez JA, Olivera M, Ladero JM, et al (1996). Increased risk for hepatacellular carcinoma in NAT2-slow acetylators and CYP2D6-rapid metabolizers. Pharmacogenetics, 6, 501-12. DOI |
59 | Zhou JL, Yao ZJ, Zeng ZP, Zhao XR (2011). Case-control study for the relationship of CYP1A1 and CYP2D6 polymorphisms with the genetic susceptibility to lung cancer. J Guangdong Phar, 27, 528-31. |
60 | Zhou SF (2009). Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet, 48, 689-723. DOI ScienceOn |
61 | Zintzaras E, Ioannidis JP (2005). Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol, 28, 123-37. DOI |
62 | Febbo PG, Kantoff PW, Giovannucci E, et al (1998). Debrisoquine hydroxylase (CYP2D6) and prostate cancer. Cancer Epidemiol Biomarkers Prev, 7, 1075-8. |
63 | Aydin-Sayitoglu M, Hatirnaz O, Erensoy N, et al (2006). Role of CYP2D6, CYP1A1, CYP2E1, GSTT1, and GSTM1 genes in the susceptibility to acute leukemias. Am J Hematol, 81, 162-70. DOI ScienceOn |
64 | Bonanni B, Macis D, Maisonneuve P, et al (2006). Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial. J Clin Oncol, 24, 3708-9. DOI |
65 | Butler WJ, Ryan P, Roberts-Thomson IC (2001). Metabolic genotypes and risk for colorectal cancer. J Gastroenterol Hepatol, 16, 631-5. DOI ScienceOn |
66 | Chen HC, Hu WX, Liu QX, et al (2008). Genetic polymorphisms of metabolic enzymes CYP1A1, CYP2D6, GSTM1 and GSTT1 and leukemia susceptibility. Eur J Cancer Prev, 17, 251-8. DOI |
67 | Chen SQ, Xu L, Ma GJ, Xue KX (2004). Genetic polymorphism of CYP2D6 and its relation to lung cancer susceptibility. Tumor Mar, 24, 96-98. |
68 | Foster BC, Vandenhoek S, Hana J, et al (2003). In vitro inhibition of human cytochrome P450-mediated metabolism of marker substrates by natural products. Phytomedicine, 10, 334-42. DOI |
![]() |